Absolute Antibody provides recombinant antibody products and services to customers around the world for pharmaceutical, diagnostic and research applications. Below are case studies and testimonials illustrating the benefits of our recombinant antibody technology.
Engineering ACE2 Fc Fusion Proteins For COVID-19 Prophylaxis
Paradigm Immunotherapeutics developed ACE2 Fc fusion proteins with extremely high affinity against SARS-CoV-2, the virus that causes COVID-19. Absolute Antibody engineered and manufactured several versions of the ACE2 Fc fusion proteins, helping Paradigm design a protein with Fc silencing and extended half-life to improve its efficacy and safety in humans. “Absolute Antibody and its CSO Mike Fiebig have an excellent understanding of Paradigm’s goals,” said Dr. Neil Bodie. “They have an uncanny ability to take my in silico optimized amino acid sequences and turn them into world-class Fc fusion proteins.”
Saving a Malaria Antibody with Therapeutic Potential
Dr. Jake Kurtis, Professor of Pathology and Laboratory Medicine at Brown University, had to abandon a promising anti-malaria antibody after the hybridoma stopped expressing. Absolute Antibody was able to recover the antibody sequence, produce a high-performing recombinant version, and develop humanized variants. “Working with Absolute Antibody was super simple,” Dr. Kurtis said. “Turnaround time was fast, the deliverables and written reports were very helpful, and the team successfully addressed all my questions about the sequence.”
Optimizing an Antibody for Glioblastoma Treatment
Dr. Mariano Viapiano of the State University of New York had developed an antibody that successfully treated glioblastoma in mouse models. Absolute Antibody provided recombinant production, chimerization and finally humanization services to develop optimized humanized antibodies with the robust manufacturability required for clinical use. ““I would absolutely recommend Absolute Antibody to another researcher,” Dr. Viapiano said. “I was kept informed of the project at each step and milestone, and the team is very efficient. Whenever they said they’re making X antibody with X features, that’s exactly what we got.”
PD-1 Fc Silent™ Antibody Improves Anti-Tumor Activity in Mice
Dr. Sophie Lucas and Dr. Grégoire de Streel are part of a research team at the de Duve Institute at UC Louvain in Belgium focusing on cancer immunotherapy research. Through their work, they have developed a monoclonal antibody targeting the GARP:TGF-β1 protein complex, in order to selectively block Treg production of the cytokine TGF-β1 and as a result induce anti-tumor activity in mouse models otherwise resistant to anti-PD-1 immunotherapy. More recently, their research showed that when this antibody is administered in combination with our anti-PD-1 Fc Silent™ antibody to tumor-bearing mice, a significantly higher proportion of mice completely and durably rejected their tumors.
Developing a Panel of Recombinant Antibody Controls for Cytokine Release Assays
The National Institute for Biological Standards and Control (NIBSC) developed the first antibody reference panel for the qualification and validation of cytokine release assays, which are critical tools for the preclinical safety assessment of novel therapeutic antibodies. Absolute Antibody was chosen to recombinantly produce the reference antibodies, manufacturing gram quantities of two research-grade biosimilar positive controls and three isotype-matched negative controls using our proprietary transient expression system.
Using Bispecific Antibody Reagents to Further Immunotherapy Research
Researchers at the Leiden University Medical Center (LUMC) in the Netherlands used Absolute Antibody’s unique murine knob-into-hole (KIH) bispecific antibody reagents to treat cancer in mouse models. The study demonstrated that T-cell-engaging CD3ε-bispecific antibodies in combination with oncolytic viruses could improve immunotherapy treatment of solid cancer tumors.
Large-Scale Production of the First Pig Influenza Antibodies
The Pirbright Institute developed the first-ever pig antibodies against influenza. The antibodies were generated from influenza-infected pigs, after which Absolute Antibody recombinantly expressed 20 different clones for evaluation in serological assays. We then manufactured a top antibody candidate in bulk quantities for further research in vivo using our transient expression system.
Converting a Popular Puromycin Antibody to Recombinant Production
Scot R. Kimball of Penn State College of Medicine developed an anti-puromycin antibody that enabled non-radioactive measurement of global protein synthesis. To ensure the longevity of this useful research tool, Absolute Antibody sequenced and recombinantly produced the antibody. We also engineered it into additional species and isotypes to open up new experimental possibilities.
Overcoming Obstacles to Antibody Production with Hybridoma Sequencing
Our next-generation sequencing has helped some of our clients sequence their hybridomas and overcome obstacles to antibody production. From an unknown isotype, to a contaminated cell line and a species switch-up, our clients come to us with many research challenges that we are able to find solutions to using our novel NGS approach.
Engineered, Species-Matched Antibody Allowed for Long-Term CD8+ T-Cell Depletion in Mice
Prof. Daniel Pinschewer at the University of Basel in Switzerland was able to successfully deplete CD8+ T-cells long-term using Absolute Antibody’s recombinant anti-CD8 depletion antibody, which was engineered to have mouse IgG2a constant domains especially suited to in vivo work. Dr. Pinschewer’s team established in mouse experiments that the chimeric antibody depleted CD8+ T-cells to below detection limits in blood for at least two months, thus for much longer periods of time than ever previously observed with the standard rat anti-CD8 antibody.
Saving CP9/19: An Antibody Sequencing Story
“The antibody CP9/19 was first characterized almost 30 years ago… It was of grave concern to Ximbio when we learnt that the rat hybridoma cells were contaminated with mouse antibody producing cells which were much more proliferative but as yet unknown. The Absolute Antibody team excelled in this project, firstly to ensure the longevity of this antibody through sequencing and secondly to enable the generation of an antibody preparation that is superior in performance to one derived from the hybridoma.” – Ximbio portfolio team member at the time of this project
Engineering a DNA/RNA G-quadruplex Antibody
The laboratory of Dr. Shankar Balasubramanian at the University of Cambridge had developed a single-chain variable fragment (scFv) antibody to detect DNA/RNA G-quadruplex. Absolute Antibody used the sequence of the antibody clone to engineer four new formats: full-length mouse IgG1, mouse Fab fragment, full-length goat IgG and human Fab fragment. All new versions were produced recombinantly and shown to effectively bind DNA/RNA G-quadruplex; they have now been used successfully by researchers around the world.